ArticleArchives of medical science : AMS2020
Contribution to determining the antioxidant capacity of melatonin in orodispersible tablets - comparison with reference antioxidants.
Article in Archives of medical science : AMS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Disorders of Endogenous and Exogenous Antioxidants in Neurological Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 2Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMelatonin is a hormone used in the treatment of diverse pathologies due to its ability to regulate numerous physiological processes related to biological rhythms and neuroendocrine function. MATERIAL AND
methodsThis study examines whether or not the antioxidant capacities of melatonin are modified during the creation of fast disintegrating oral tablets (FDDTs) through direct compression in which different concentrations of the active substance (3, 5, 10 and 60 mg) and excipients are made. In addition, the antioxidant capacity of melatonin is compared with that of reference antioxidants such as vitamin C, Trolox, resveratrol, glutathione and nicotinamide adenine dinucleotide phosphate (NADPH).
resultsMelatonin has a lower antioxidant capacity only 5% of the capacity of resveratrol. Resveratrol is the compound having the greatest antioxidant capacity. As for the influence of the tablets components, it was found that only at higher concentrations of melatonin (60 mg/tablet), with the excipients mannitol, polyvinylpyrrolidone (crospovidone), magnesium stearate and anhydrous colloidal silica, did a decrease occur in the antioxidant capacity value, possibly due to the lower percentage of these excipients in the formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.